Valneva

Valneva Operating Cash Flow

The Operating Cash Flow of Valneva (VLA.PA) as of Oct 31, 2026 is -52.89 M EUR. In the previous year, Operating Cash Flow was -67.22 M EUR — a change of -21.31% (higher).

Operating Cash Flow

-52.89 MEUR

YoY

-21.31%

Last updated:

Operating Cash Flow of Valneva is 2025 -52.89 M EUR. Operating Cash Flow of Valneva was 2024 -67.22 M EUR. It decreases by -21.31% higher compared to the previous year.

The Valneva Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
16.31 M EUR
Jan 1, 2019
5.53 M EUR
Jan 1, 2020
137.74 M EUR
Jan 1, 2021
76.90 M EUR
Jan 1, 2022
-245.34 M EUR
Jan 1, 2023
-202.74 M EUR
Jan 1, 2024
-67.22 M EUR
Jan 1, 2025
-52.89 M EUR
The Valneva Operating Cash Flow history
YEAROperating Cash FlowYoY
-52.89 MEUR-21.31%
-67.22 MEUR-66.85%
-202.74 MEUR-17.36%
-245.34 MEUR-419.04%
76.90 MEUR-44.17%
137.74 MEUR+2,391.19%
5.53 MEUR-66.09%
16.31 MEUR+27.10%
12.83 MEUR+97.22%
6.51 MEUR-126.73%
-24.33 MEUR+62.83%
-14.94 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Operating Cash Flow of Valneva is -52.89 M EUR in 2025.

Operating Cash Flow of Valneva changed from -67.22 M EUR to -52.89 M EUR, representing a -21.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Valneva since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Valneva historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valneva

All Key Metrics — Valneva